Skip to Content


In the US, FIRMAGON (degarelix systemic) is a member of the following drug classes: gonadotropin-releasing hormone antagonists, hormones/antineoplastics and is used to treat Prostate Cancer.

US matches:

UK matches:

Ingredient matches for FIRMAGON


Degarelix is reported as an ingredient of FIRMAGON in the following countries:

  • Argentina
  • Brazil
  • Cyprus
  • Greece
  • Hong Kong
  • Malaysia
  • Peru
  • Poland
  • Portugal
  • Serbia
  • Singapore
  • Slovakia
  • Thailand

Degarelix acetate (a derivative of Degarelix) is reported as an ingredient of FIRMAGON in the following countries:

  • Australia
  • Belgium
  • Bosnia & Herzegowina
  • Canada
  • Croatia (Hrvatska)
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Iceland
  • Ireland
  • Lithuania
  • Macedonia
  • Netherlands
  • Norway
  • Romania
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • United Kingdom
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.